References: Neuroblastoma

American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society; 2016.

Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–257.

Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia Pa: Lippincott Williams & Wilkins; 2011:886–922.

Cheung NK, Dyer MA. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411.

Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062–1071.

Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG task force report. J Clin Oncol. 2009; 27: 289–297.

Dome JS, Rodriguez-Galindo C, Spunt SL, Santana VM. Pediatric solid tumors. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2091–2096.

Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of pediatric cancers: A meta-analysis. Clin Pharmacol Ther. 2007;81:685–691.

Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999. Accessed at on November 20, 2013.

Grupp SA, Dvorak CC, Nieder ML, et al. Children’s Oncology Group’s 2013 blueprint for research: Stem cell transplantation. Pediatr Blood Cancer. 2013;60:1044–1047.

Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211.

Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–2120.

Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–2593.

Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: Challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35:337–347.

Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG task force report. J Clin Oncol. 2009; 27: 298–303.

Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children’s Oncology Group phase I consortium study. J Clin Oncol. 2012;30 (suppl; abstr 9500).

Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935.

National Cancer Institute. Physician Data Query (PDQ). Neuroblastoma Treatment. 2013. Accessed at on November 20, 2013.

Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: A Children’s Oncology Group study. Ann Surg. 2012;256:573–580.

Park JR, Bagatell R, London WB, et al. Children’s Oncology Group’s 2013 blueprint for research: Neuroblastoma. Pediatr Blood Cancer. 2013;60:985–993.

Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008;112:2796–2801.

Shusterman S, London WB, Gillies SD, et al. Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969-4975.

Wang LL, Yustein J, Louis C, et al. Solid tumors of childhood: Neuroblastoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1760–1766.

Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in
incidence as a result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209–1214.

Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.